About Veritas Pharma Inc.

Veritas Approach

Veritas Pharma is led by a strong management and a renowned team of scientists to address the critical need for real science to support medical marijuana claims. Our mission is to develop and commercialize the most effective cannabis strains. Veritas Cannabis clinical development pipeline include:

  • Chronic Pain (e.g. cancer pain)
  • Nausea & Vomiting
  • Muscle Spasms
  • Epilepsy
  • Post-Traumatic Stress Disorder (PTSD)

 

The Market

As public perception and patient preference continues to trend positively towards the medical use of marijuana, many analyst believe that the currently $2.9bn industry* is on the verge of rapid growth. This projected growth is further assisted by the continued liberalization of cannabis laws at the national and state levels within North America. Canada has a national medical cannabis program and a newly elected prime minister who has stated his intents on legalizing recreational use of cannabis. In the United States, thus far 39 states have legalized cannabis either for recreational or medicinal use, despite Cannabis being federally classified as a schedule 1 substance under the Controlled Substances Act.

 

Veritas’ immediate aim is to develop cannabis strains that specifically target cancer pain and nausea. Currently, cancer pain is the largest segment of the opioid market. However, with the increasing public concern over the continued use of opioids for pain treatment a trend towards alternative treatments is expected.

If we can say, Yes, these particular cultivars are effective and work and can save patients’ lives or make lives better, improving their quality of life. That’s something worth investigating and pursuing. That’s what drives me.

Dr. Dom Spina

Director

Our Research and development approach

Veritas innovative research and development approach aims to solve the critical need for real science to support claims surrounding medical marijuana. Our scientific approach combined with our strategic alliances intends to effectively address the concerns over the medical industry’s varied output in content and quality, potency and efficacy.

 

Three-pronged Approach to Research and Development:

First, we aim to chemically profile different marijuana cultivars.

Subsequently, those same cultivars will pharmacologically be profiled in the search for disease specific strains.

Finally, we aim to perform clinical trials to establish the clinical utility of each cultivar.

This unique approach has the advantage of being low cost, and allows for faster market entry, providing doctors and patients with conclusive scientific evidence to recommend and use our proprietary medical cannabis strains with confidence. Similarly, the presence of conclusive scientific evidence could potentially develop the platform allowing coverage through medical insurance providers.

 

  • de Bruin D, Ahmad T, Avendano JE, Sajanial M, Edelstein A, Ryskin M. 2015. Bank of America Report Is Bullish on Cannabis Testing. Biotech Business Week, Dec. 3, ,pp. 1–45

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!